Effect of Pablociclib in Endocrine Resistant Patients - A Panel Discussion

Speciality: Oncology

Description:

Welcome to an insightful panel discussion on the role of palbociclib in treating endocrine-resistant breast cancer. Leading oncologists Dr. Srinivas K G, Dr. Abhaya Kumar S M, and Dr. Vishwanath S, delve into the complexities of hormone receptor-positive, HER2-negative breast cancer, analyzing the results of the clinical trial and exploring optimal treatment strategies in the face of endocrine resistance. The panel offers a comprehensive overview of the trial, including patient selection criteria, primary endpoints, and a detailed analysis of the outcomes. 

This video provides a critical analysis of the trial's findings, exploring potential reasons for the observed results and discussing the implications for clinical practice. The experts debate the optimal duration of palbociclib treatment and its role in managing patients with hormone receptor-positive breast cancer. They also address the challenges in pathways development for advanced breast cancer.

Gain valuable insights from these leading experts to enhance your understanding of endocrine-resistant breast cancer and the role of palbociclib. Don't miss this opportunity to expand your knowledge and improve patient care. Be sure to watch the entire video and subscribe for more expert-led discussions on cutting-edge oncology topics.
 

See More Webinars @ Hidoc Webinars